Last reviewed · How we verify
NCT06378060
Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia
Phase 2 trial testing Modified transplantation system in Severe Aplastic Anemia in 30 participants. Currently enrolling.
1 April 2026
Quick facts
| Lead sponsor | Hematology department of the 920th hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 March 2024 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 April 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Modified transplantation system — full drug profile →
Conditions studied
- Severe Aplastic Anemia — all drugs for Severe Aplastic Anemia →
Sponsor
Hematology department of the 920th hospital
Who can join
Adults 3 to 65, any sex, with Severe Aplastic Anemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study was to evaluate the safety and efficacy of a modified allogeneic hematopoietic stem cell transplantation regimen for aplastic anemia.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Publication Only
· 2025
Verify or expand the search:
- PubMed search for NCT06378060
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Modified transplantation system
Trials testing the same drug.
- NCT06837987 — Modified Transplantation Regimen and aGVHD Prophylaxis for Severe Aplastic Anemia in the Setting of Allogeneic HSCT. · completed
Other recruiting trials for Severe Aplastic Anemia
Currently open trials in the same condition.
- NCT06622694 — CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia · Phase 1 · recruiting
- NCT06517641 — Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia · Phase 2 · recruiting
- NCT06695741 — Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia · Phase 2 · recruiting
- NCT06412497 — MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Se · Phase 2 · recruiting
- NCT05998408 — JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure · Phase 1, PHASE2 · recruiting
Other Hematology department of the 920th hospital trials
Trials by the same sponsor.
- NCT06476249 — Risk Factors for Postoperative Cough in Patients Undergoing Thoracoscopic Lung Resection · recruiting
- NCT06164821 — Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemia · NA · unknown
- NCT05807347 — Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia · Phase 2 · unknown
- NCT05662956 — A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients · Phase 2 · completed
- NCT06837987 — Modified Transplantation Regimen and aGVHD Prophylaxis for Severe Aplastic Anemia in the Setting of Allogeneic HSCT. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06378060 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hematology department of the 920th hospital
- Last refreshed: 22 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06378060.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing